Skip to main content

Chronic Atrophic Gastritis

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Trio Medicines
Trio MedicinesUK - London
2 programs
YF476PHASE_21 trial
YF476PHASE_21 trial
Active Trials
NCT01444014Terminated8Est. May 2012
NCT01339169Completed8Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Trio MedicinesYF476
Trio MedicinesYF476

Clinical Trials (2)

Total enrollment: 16 patients across 2 trials

YF476 and Type I Gastric Carcinoids (Norway)

Start: Jun 2011Est. completion: May 20128 patients
Phase 2Terminated

YF476 and Type I Gastric Carcinoids

Start: Jan 2011Est. completion: Dec 20138 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.